Cargando…

Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis

Chronic lymphocytic leukemia (CLL) is the most common lymphoproliferative disease in adults. Despite durable responses and sustained remission rates to frontline therapy, CLL is still incurable within standard therapy and eventually relapses. Maintenance therapies aim to achieve deep remission. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Tsung-Ying, Jhou, Hong-Jie, Chen, Po-Huang, Lee, Cho-Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222174/ https://www.ncbi.nlm.nih.gov/pubmed/35735448 http://dx.doi.org/10.3390/curroncol29060339

Ejemplares similares

PB1873: EFFECTS OF LENALIDOMIDE MAINTENANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A TRIAL-SEQUENTIAL ANALYSIS
por: Lee, C.-H., et al.
Publicado: (2022)

A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia
por: Lee, Cho-Hao, et al.
Publicado: (2020)

Lenalidomide and Chronic Lymphocytic Leukemia
por: González-Rodríguez, Ana Pilar, et al.
Publicado: (2013)

Lenalidomide in the Treatment of Chronic Lymphocytic Leukemia
por: Cortelezzi, Agostino, et al.
Publicado: (2012)

Endovascular thrombectomy for basilar-artery occlusion: A meta-analysis with trial sequential analysis
por: Wang, Wei-Sheng, et al.
Publicado: (2023)

Proportional assist ventilation versus pressure support ventilation for weaning from mechanical ventilation in adults: a meta-analysis and trial sequential analysis
por: Ou-Yang, Liang-Jun, et al.
Publicado: (2020)

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial
por: Pettitt, Andrew R., et al.
Publicado: (2020)

PB2697: LONG TERM PEJORATIVE IMPACT OF LENALIDOMIDE MAINTENANCE ON HEALTH-RELATED QUALITY OF LIFE IN CHRONIC LYMPHOCYTIC LEUKEMIA. ANCILLARY STUDY OF THE PHASE III CLL6-RESIDUUM TRIAL
por: Wasse, Stephane, et al.
Publicado: (2023)

Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial
por: Schroeder, Thomas, et al.
Publicado: (2023)

Sequential and combination treatments with novel agents in chronic lymphocytic leukemia
por: Fürstenau, Moritz, et al.
Publicado: (2019)

Treatment Outcomes of Novel Targeted Agents in Relapse/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-Analysis
por: Chen, Po-Huang, et al.
Publicado: (2019)

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia
por: Medeiros, Bruno C., et al.
Publicado: (2018)

Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)
por: Chanan-Khan, A, et al.
Publicado: (2017)

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
por: Egle, Alexander, et al.
Publicado: (2018)

Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy
por: Oka, Satoko, et al.
Publicado: (2019)

An Urologic Face of Chronic Lymphocytic Leukemia: Sequential Prostatic and Penis Localization
por: D’Arena, Giovanni, et al.
Publicado: (2013)

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial
por: Bühler, A, et al.
Publicado: (2016)

Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis
por: Xie, Chun-Hong, et al.
Publicado: (2018)

Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells
por: Acebes-Huerta, Andrea, et al.
Publicado: (2014)

Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
por: Winqvist, Maria, et al.
Publicado: (2016)

The CXCR4–STAT3–IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide
por: Shaim, Hila, et al.
Publicado: (2018)

Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia
por: Villa-Álvarez, Mónica, et al.
Publicado: (2018)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia
por: Jain, Prachi, et al.
Publicado: (2017)

Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome
por: Pham, Brian, et al.
Publicado: (2021)

Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis
por: Bonello, Francesca, et al.
Publicado: (2019)

Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies
por: McDaniel, Jessica M., et al.
Publicado: (2012)

Association between nitric oxide synthase T-786C genetic polymorphism and chronic kidney disease: Meta-analysis incorporating trial sequential analysis
por: Hsiao, Po-Jen, et al.
Publicado: (2021)

Lenalidomide Treatment for Multiple Myeloma: Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Yang, Bo, et al.
Publicado: (2013)

Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study
por: van Oers, Marinus, et al.
Publicado: (2019)

Methods of Weaning From Mechanical Ventilation in Adult: A Network Meta-Analysis
por: Jhou, Hong-Jie, et al.
Publicado: (2021)

Extrapyramidal Symptoms with Administration of Lenalidomide Maintenance Therapy for Multiple Myeloma
por: Sagar, FNU, et al.
Publicado: (2018)

Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma
por: Cai, Jiao, et al.
Publicado: (2021)

Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features
por: Khan, Abdullah M., et al.
Publicado: (2018)

Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials
por: Htut, Thura Win, et al.
Publicado: (2021)

Trial Sequential Analysis in systematic reviews with meta-analysis
por: Wetterslev, Jørn, et al.
Publicado: (2017)

Trial sequential analysis: novel approach for meta-analysis
por: Kang, Hyun
Publicado: (2021)

Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial
por: Hunault-Berger, M, et al.
Publicado: (2017)

Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients
por: Zhou, Qiaolin, et al.
Publicado: (2022)

P978: IXAZOMIB VERSUS LENALIDOMIDE OR IXAZOMIB AND LENALIDOMIDE COMBINATION AS MAINTENANCE REGIMEN FOR PATIENTS WITH MULTIPLE MYELOMA: INTERIM ANALYSIS OF A MULTI-CENTER PROSPECTIVE STUDY IN CHINA
por: Zhuang, Z., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qno0p727vd3gjdliv0uhr48ocv